trial

The Phase I Study of HS-10509 in Chinese Adult Subjects

NCTId NCT06301074
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Unknown
Enrollment 80 (estimated)
Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.
Primary completion 2024-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Unknown
Enrollment
80 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2024-03
Primary completion
2024-05
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
HS-10509

Sponsors

Jiangsu Hansoh Pharmaceutical Co., Ltd.Lead Sponsor

Investigators

1
Xiaojiao Li, Dr.Principal Investigator

Sites

1 total
Changchun, China

Facts & assertions

4 sourced
Enrollment
80
Phase
PHASE1
Primary Completion Date
2024-05
Status
UNKNOWN
relationships
The graph out of here
drug
HS-10509
drug
lead_sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Xiaojiao Li, Dr.
person